• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    7/17/23 5:32:34 PM ET
    $ABOS
    $ARDS
    $CDIO
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABOS alert in real time by email

    Gainers

    • Aridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 89.5% to $0.5 during Monday's after-market session. At the close, Aridis Pharmaceuticals's trading volume reached 8.1 million shares. This is 212.0% of its average volume over the last 100 days. The company's market cap stands at $18.0 million.
    • Dare Bioscience (NASDAQ:DARE) stock moved upwards by 7.72% to $0.92. The company's market cap stands at $79.3 million.
    • Karyopharm Therapeutics (NASDAQ:KPTI) stock rose 6.53% to $1.63. Trading volume for this security closed at 514.4K, accounting for 17.8% of its average full-day volume over the last 100 days. The company's market cap stands at $185.8 million.
    • Cue Health (NASDAQ:HLTH) stock rose 5.45% to $0.45. The company's market cap stands at $67.9 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock rose 5.17% to $1.22. The company's market cap stands at $12.1 million.
    • Petros Pharma (NASDAQ:PTPI) shares rose 4.98% to $3.58. The company's market cap stands at $7.5 million.

    Losers

    • 9 Meters Biopharma (NASDAQ:NMTR) shares fell 60.0% to $0.25 during Monday's after-market session. 9 Meters Biopharma's trading volume hit 886.9K shares by close, accounting for 1142.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.6 million.
    • Masimo (NASDAQ:MASI) stock fell 24.92% to $110.5. Masimo's trading volume hit 84.8K shares by close, accounting for 18.1% of its average volume over the last 100 days. The company's market cap stands at $5.8 billion.
    • CEL-SCI (AMEX:CVM) shares fell 21.33% to $2.25. At the close, CEL-SCI's trading volume reached 388.8K shares. This is 210.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $100.6 million.
    • EUDA Health Holdings (NASDAQ:EUDA) stock fell 16.41% to $0.51. This security traded at a volume of 1.1 million shares come close, making up 248.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.6 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares decreased by 16.08% to $0.68. This security traded at a volume of 153.5K shares come close, making up 8.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $2.8 million.
    • Acumen Pharmaceuticals (NASDAQ:ABOS) stock declined by 9.68% to $8.78. Acumen Pharmaceuticals's trading volume hit 12.7 million shares by close, accounting for 4221.5% of its average volume over the last 100 days. The company's market cap stands at $360.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS
    $ARDS
    $CDIO
    $CVM

    CompanyDatePrice TargetRatingAnalyst
    Masimo Corporation
    $MASI
    3/27/2026Outperform → Mkt Perform
    Raymond James
    Karyopharm Therapeutics Inc.
    $KPTI
    3/10/2026$28.00Buy
    Rodman & Renshaw
    Karyopharm Therapeutics Inc.
    $KPTI
    2/5/2026Overweight
    Cantor Fitzgerald
    Masimo Corporation
    $MASI
    11/17/2025Neutral
    BofA Securities
    Karyopharm Therapeutics Inc.
    $KPTI
    10/13/2025$15.00Neutral → Buy
    H.C. Wainwright
    Karyopharm Therapeutics Inc.
    $KPTI
    7/16/2025Buy → Neutral
    H.C. Wainwright
    Karyopharm Therapeutics Inc.
    $KPTI
    7/11/2025$27.00Buy
    H.C. Wainwright
    Acumen Pharmaceuticals Inc.
    $ABOS
    6/17/2025$4.00Buy
    Citigroup
    More analyst ratings

    $ABOS
    $ARDS
    $CDIO
    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABOS
    $ARDS
    $CDIO
    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

    Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

    3/26/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

    Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioCash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) --  Acumen Pharmaceut

    3/26/26 7:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Karyopharm Announces $30 Million Private Placement with RA Capital

    NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full.In the private placement, the Company agreed to sell 1,030,354 shares of common stock at a price of $6.785 per share, 3,391,164 pre-funded warrants at a price of

    3/24/26 7:01:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ARDS
    $CDIO
    $CVM
    SEC Filings

    View All

    SEC Form 1-A POS filed by Dare Bioscience Inc.

    1-A POS - Dare Bioscience, Inc. (0001401914) (Filer)

    3/27/26 7:20:30 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 253G2 filed by Dare Bioscience Inc.

    253G2 - Dare Bioscience, Inc. (0001401914) (Filer)

    3/27/26 7:15:21 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Masimo Corporation

    SCHEDULE 13G/A - MASIMO CORP (0000937556) (Subject)

    3/27/26 10:33:47 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABOS
    $ARDS
    $CDIO
    $CVM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ARDS
    $CDIO
    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tay Whye Shin

    3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    3/18/26 4:17:02 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Liew Kwong Yeow

    3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    3/18/26 4:16:39 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Lew Chern Yong

    3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    3/18/26 4:16:22 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    $ABOS
    $ARDS
    $CDIO
    $CVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Masimo downgraded by Raymond James

    Raymond James downgraded Masimo from Outperform to Mkt Perform

    3/27/26 8:44:43 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Rodman & Renshaw initiated coverage on Karyopharm Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $28.00

    3/10/26 8:41:07 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics

    Cantor Fitzgerald initiated coverage of Karyopharm Therapeutics with a rating of Overweight

    2/5/26 6:58:02 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ARDS
    $CDIO
    $CVM
    Leadership Updates

    Live Leadership Updates

    View All

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board

    BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors. These leadership appointments reflect a pivotal moment for Clairity following FDA De Novo authorization of its mammography-based AI risk prediction platform and increasing engagement with health systems and partners worldwide. Clairity's innovation aligns with national priorities to improve health o

    1/21/26 4:30:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

    NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A. The addition of Dr. Golumbeski brings the Acumen Board to eight members. "I am very pleased to welcome Dr. Golumbeski to th

    11/10/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $ARDS
    $CDIO
    $CVM
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

    Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

    3/26/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

    Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioCash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) --  Acumen Pharmaceut

    3/26/26 7:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

    – While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib –– Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib –– Evidence of Potential Disease Modification with More Patients Achieving ≥20% Reductions in VAF as Early as Week 24 versus Ruxolitinib –– No New Safety Signals Identified –– Karyopharm will Meet with the FDA to Discuss the Totality of the Data and Potential sNDA Filing – – Conference Call Scheduled for Today at 8:00 a.m. ET –NEWTON, Mass., M

    3/24/26 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ARDS
    $CDIO
    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

    SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

    11/14/24 4:46:40 PM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/14/24 4:22:08 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care